Who is sponsoring NCT05851391?

NCT05851391 is sponsored by University of California, San Francisco.

What drugs are being tested in NCT05851391?

Interventions in NCT05851391: Burst Suppression EEG Target Intravenous Anesthesia, Seizure Suppression EEG Target Intravenous Anesthesia.

What condition does NCT05851391 study?

NCT05851391 studies Hypoxia-Ischemia, Brain, Heart Arrest, Status Epilepticus, Refractory Status Epilepticus, Seizures, Anoxic-Ischemic Encephalopathy, Anoxia-Ischemia, Cerebral.

Is NCT05851391 still recruiting?

NCT05851391 is currently recruiting now. Last updated 15 May 2025.

Last reviewed 2025-05-15 · How we verify

NCT05851391: RESTORE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

buRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest

Recruiting now Phase 2 Last updated 15 May 2025

What this trial tests

Phase 2 trial testing Burst Suppression EEG Target Intravenous Anesthesia in Hypoxia-Ischemia, Brain in 30 participants. Currently enrolling.

Timeline

7 August 2023

Primary endpoint
30 November 2026

30 April 2027

Quick facts

Lead sponsor	University of California, San Francisco
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	30
Start date	7 August 2023
Primary completion	30 November 2026
Estimated completion	30 April 2027
Sites	1 location across United States

Drugs / interventions tested

Burst Suppression EEG Target Intravenous Anesthesia — full drug profile →
Seizure Suppression EEG Target Intravenous Anesthesia — full drug profile →

Conditions studied

Hypoxia-Ischemia, Brain — all drugs for Hypoxia-Ischemia, Brain →
Heart Arrest — all drugs for Heart Arrest →
Status Epilepticus — all drugs for Status Epilepticus →
Refractory Status Epilepticus — all drugs for Refractory Status Epilepticus →

Sponsor

University of California, San Francisco

Who can join

18 and older, any sex, with Hypoxia-Ischemia, Brain or Heart Arrest. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RESTORE is a randomized clinical trial investigating the safety and feasibility of using EEG treatment targets (burst suppression vs. seizure suppression) for post-cardiac arrest refractory status epilepticus treatment.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Advances in Therapies to Treat Neonatal Hypoxic-Ischemic Encephalopathy.
Ranjan AK, Gulati A. · · 2023 · cited 41× · PMID 37892791 · DOI 10.3390/jcm12206653
Anesthetics in status epilepticus: does one size fits it all?-A scoping review on titration goals, timing, and patient selection.
Fisch U, De Stefano P, Baumann SM, Rüegg S, et al · · 2026 · PMID 42051778 · DOI 10.3389/fneur.2026.1805775

Verify or expand the search:

Other recruiting trials for Hypoxia-Ischemia, Brain

Currently open trials in the same condition.

NCT06469801 — ECMO ABI Detection With Hyperfine · NA · recruiting
NCT06984445 — Cord Blood S100B Protein Levels in Neonates Following Intrauterine Transfusions for HDFN-Associated Fetal Anemia · recruiting
NCT06893926 — Cord Blood S100B Protein Concentration in Neonates With Fetal Growth Restriction · recruiting
NCT05376267 — Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) · NA · recruiting
NCT05413733 — Neuropsychological Rehabilitation Over the Internet · NA · active not recruiting

Other University of California, San Francisco trials

Trials by the same sponsor.

NCT05284773 — Screening for Acute Malnutrition · NA · withdrawn
NCT04634851 — Video Home Visits for Dietary Counselling · NA · not yet recruiting
NCT06065670 — Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a M · Phase 1, PHASE2 · not yet recruiting
NCT07534098 — Intervention for Hearing Health Among Native Americans · NA · not yet recruiting
NCT06960421 — Exercise-based Frailty Intervention in Lung Transplantation (XFIT) · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05851391 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, San Francisco
Last refreshed: 15 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05851391.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing